Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
Aspira Women’s Health Inc. (Nasdaq: AWH) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). This designation acknowledges Aspira’s position as an innovator in women’s health and provides new opportunities for funding, thought leadership, and networking.
The Investor Catalyst Hub, based in the Greater Boston area and managed by VentureWell, aims to accelerate the commercialization of groundbreaking biomedical solutions. As a spoke, Aspira gains access to potential funding, flexible contracting, and opportunities to provide input on ARPA-H challenge areas and priorities. The company joins a diverse network of organizations aligned with ARPA-H’s mission to improve health outcomes through research focus areas such as health science futures, proactive health, scalable solutions, and resilient systems.
Aspira Women’s Health Inc. (Nasdaq: AWH) è stata selezionata come un polo per l’Investor Catalyst Hub, un hub regionale di ARPANET-H, una rete nazionale di innovazione nel settore della salute lanciata dall’Advanced Research Projects Agency for Health (ARPA-H). Questa designazione riconosce la posizione di Aspira come innovatrice nella salute delle donne e offre nuove opportunità di finanziamento, leadership di pensiero e networking.
L’Investor Catalyst Hub, situato nella Greater Boston area e gestito da VentureWell, mira ad accelerare la commercializzazione di soluzioni biomediche innovative. In qualità di polo, Aspira ha accesso a potenziali finanziamenti, contratti flessibili e opportunità di fornire input sulle aree e le priorità delle sfide dell’ARPA-H. L’azienda entra a far parte di una rete diversificata di organizzazioni allineate alla missione dell’ARPA-H di migliorare gli esiti sanitari attraverso aree di ricerca focalizzate come le scienze della salute del futuro, la salute proattiva, soluzioni scalabili e sistemi resilienti.
Aspira Women’s Health Inc. (Nasdaq: AWH) ha sido seleccionada como un nodo para el Investor Catalyst Hub, un centro regional de ARPANET-H, una red nacional de innovación en salud lanzada por la Advanced Research Projects Agency for Health (ARPA-H). Esta designación reconoce la posición de Aspira como innovadora en la salud de las mujeres y proporciona nuevas oportunidades para financiamiento, liderazgo de pensamiento y redes de contacto.
El Investor Catalyst Hub, ubicado en el área de Greater Boston y gestionado por VentureWell, tiene como objetivo acelerar la comercialización de soluciones biomédicas innovadoras. Como nodo, Aspira obtiene acceso a financiamiento potencial, contratos flexibles y oportunidades para ofrecer información sobre las áreas y prioridades de desafío de ARPA-H. La empresa se une a una red diversa de organizaciones alineadas con la misión de ARPA-H de mejorar los resultados de salud a través de áreas de investigación centradas en el futuro de la ciencia de la salud, la salud proactiva, soluciones escalables y sistemas resilientes.
Aspira Women’s Health Inc. (Nasdaq: AWH)가 Investor Catalyst Hub의 스포크로 선정되었습니다. 이는 ARPANET-H의 지역 허브로, 첨단 연구 프로젝트 기구인 건강을 위한 ARPA-H에 의해 시작된 전국적인 건강 혁신 네트워크입니다. 이 지정은 여성 건강 분야의 혁신가로서의 Aspira의 입장을 인정하며, 자금 지원, 사고 리더십 및 네트워킹을 위한 새로운 기회를 제공합니다.
Greater Boston 지역에 위치하고 VentureWell이 관리하는 Investor Catalyst Hub는 혁신적인 생물 의학 솔루션의 상용화를 가속화하는 것을 목표로 합니다. 스포크로서 Aspira는 잠재적인 자금 지원, 유연한 계약 및 ARPA-H의 도전 분야와 우선사항에 대한 의견을 제공할 수 있는 기회를 갖게 됩니다. 이 회사는 건강 과학의 미래, 적극적인 건강, 확장 가능한 솔루션 및 회복력 있는 시스템과 같은 연구 중심 분야를 통해 건강 결과를 개선하는 ARPA-H의 사명에 맞추어진 다양한 조직 네트워크에 합류하게 됩니다.
Aspira Women’s Health Inc. (Nasdaq: AWH) a été sélectionnée comme une antenne pour le Investor Catalyst Hub, un hub régional d’ARPANET-H, un réseau national d’innovation en santé lancé par l’Advanced Research Projects Agency for Health (ARPA-H). Cette désignation reconnaît la position d’Aspira en tant qu’innovateur dans le domaine de la santé des femmes et offre de nouvelles opportunités de financement, de leadership de pensée et de mise en réseau.
Le Investor Catalyst Hub, situé dans la région du Grand Boston et géré par VentureWell, vise à accélérer la commercialisation de solutions biomédicales révolutionnaires. En tant qu’antenne, Aspira a accès à des financements potentiels, des contrats flexibles et des opportunités de contribuer aux domaines de défi et priorités de l’ARPA-H. L’entreprise rejoint un réseau diversifié d’organisations alignées sur la mission de l’ARPA-H d’améliorer les résultats en matière de santé grâce à des domaines de recherche tels que les futures des sciences de la santé, la santé proactive, des solutions évolutives et des systèmes résilients.
Aspira Women’s Health Inc. (Nasdaq: AWH) wurde als Anlaufstelle für den Investor Catalyst Hub ausgewählt, ein regionales Zentrum von ARPANET-H, einem landesweiten Netzwerk für Gesundheitsinnovation, das von der Advanced Research Projects Agency for Health (ARPA-H) ins Leben gerufen wurde. Diese Auszeichnung anerkennt Aspiras Position als Innovatorin im Bereich der Frauengesundheit und bietet neue Möglichkeiten für Finanzierung, Gedankenführung und Networking.
Der Investor Catalyst Hub, der sich im Raum Greater Boston befindet und von VentureWell geleitet wird, hat das Ziel, die Vermarktung bahnbrechender biomedizinischer Lösungen zu beschleunigen. Als Anlaufstelle erhält Aspira Zugang zu potenziellen Finanzierungen, flexiblen Verträgen und Möglichkeiten, Input zu den Herausforderungen und Prioritäten von ARPA-H zu geben. Das Unternehmen tritt einem vielfältigen Netzwerk von Organisationen bei, die mit der Mission von ARPA-H übereinstimmen, die Gesundheitsresultate durch Forschungsfokusbereiche wie Gesundheit der Zukunft, proaktive Gesundheit, skalierbare Lösungen und widerstandsfähige Systeme zu verbessern.
Positive
- Selection as a spoke for the Investor Catalyst Hub, providing new opportunities for funding and networking
- Access to potential funding and flexible contracting for faster award execution
- Opportunity to provide input on ARPA-H challenge areas and priorities
- Alignment with ARPA-H’s mission to improve health outcomes through various research focus areas
Aspira Women’s Health’s selection as a spoke for the Investor Catalyst Hub is a neutral development for the company. While it offers potential benefits like networking and funding opportunities, the immediate financial impact is unclear. The hub’s focus on accelerating healthcare innovation aligns well with Aspira’s AI-powered diagnostic solutions for gynecologic health, potentially enhancing their industry position. However, the tangible outcomes and timeline for realizing these benefits remain uncertain.
Investors should note that this partnership could lead to future growth opportunities and increased visibility in the women’s health sector. The association with ARPA-H may also lend credibility to Aspira’s innovative approach. Yet, it’s important to remember that this designation doesn’t guarantee immediate revenue growth or market success. The long-term value will depend on how effectively Aspira leverages this opportunity to advance its diagnostic tools and expand its market presence.
“Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of nonprofit organizations and Minority-Serving Institutions, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.
“It is an honor to join the Investor Catalyst Hub alongside so many of healthcare’s most impactful organizations. Our mission to radically improve gynecologic health outcomes through the development of AI-powered diagnostic solutions is perfectly aligned with the objectives of the Hub, and we look forward to playing a leadership role in the acceleration of progress across the entire ecosystem,” stated Nicole Sandford, Aspira’s CEO.
Aspira joins a dynamic nationwide network of organizations aligned to ARPA-H’s overarching mission to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions, and resilient systems. Investor Catalyst Hub spokes represent a broad spectrum of expertise, geographic diversity, and community perspectives.
“Our spoke network embodies a rich and representative range of perspectives and expertise,” said Mark Marino, Vice President of Growth Strategy and Development for VentureWell and Project Director for the Investor Catalyst Hub. “Our spokes comprise a diverse network that will be instrumental in ensuring that equitable health solutions reach communities across every state and tribal nation.”
As an Investor Catalyst Hub spoke, Aspira gains access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. Spoke membership also offers opportunities to provide input on ARPA-H challenge areas and priorities, along with access to valuable networking opportunities and a robust resource library. The spoke network will continue to grow as the Investor Catalyst Hub expands its efforts, with applications being selected on a rolling basis. Interested organizations can visit to learn more or submit a membership application.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. Aspira’s other in-development endometriosis test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve a number of risks and uncertainties. Such forward-looking statements include statements regarding, among other things, the timing and completion of any products in the pipeline development and other statements that are predictive in nature. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as “designed to,” “expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release and other factors that may cause such differences include the satisfaction of customary closing conditions related to the offering and the expected timing of the closing of the offering. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 10-K, for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Aspira presently does not know, or that Aspira currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Aspira’s expectations, plans, or forecasts of future events and views as of the date of this press release. Subsequent events and developments may cause the Company’s assessments to change. However, while Aspira may elect to update these forward-looking statements at some point in the future, Aspira expressly disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Aspira’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Relations Contact:
Monique Kosse
Investor Relations Specialist
[email protected]
FAQ
What is the significance of Aspira Women’s Health (AWH) being selected as a spoke for the Investor Catalyst Hub?
Being selected as a spoke acknowledges Aspira’s position as an innovator in women’s health and provides new opportunities for funding, thought leadership, and networking with other healthcare industry leaders. It also gives Aspira access to potential funding, flexible contracting, and the ability to provide input on ARPA-H challenge areas and priorities.
How does the Investor Catalyst Hub benefit Aspira Women’s Health (AWH)?
The Investor Catalyst Hub provides Aspira with access to potential funding, flexible contracting for faster award execution, opportunities to provide input on ARPA-H challenge areas and priorities, valuable networking opportunities, and access to a robust resource library.
What is the mission of Aspira Women’s Health (AWH) in relation to the Investor Catalyst Hub?
Aspira’s mission is to radically improve gynecologic health outcomes through the development of AI-powered diagnostic solutions, which aligns with the objectives of the Investor Catalyst Hub to accelerate the commercialization of groundbreaking and accessible biomedical solutions.
What is ARPANET-H and how is it related to Aspira Women’s Health (AWH)?
ARPANET-H is a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). The Investor Catalyst Hub, of which Aspira is now a spoke, is a regional hub of ARPANET-H, aiming to accelerate the commercialization of biomedical solutions and improve health outcomes.
link